Literature DB >> 11328948

von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

H M Tsai1, W L Chandler, R Sarode, R Hoffman, S Jelacic, R L Habeeb, S L Watkins, C S Wong, G D Williams, P I Tarr.   

Abstract

Hemolytic uremic syndrome (HUS) usually occurs after infection with Shiga toxin-producing bacteria. Thrombotic thrombocytopenic purpura, a disorder with similar clinical manifestations, is associated with deficient activity of a circulating metalloprotease that cleaves von Willebrand factor at the Tyr842-Met843 peptide bond in a shear stress-dependent manner. We analyzed von Willebrand factor-cleaving metalloprotease activity and the status of von Willebrand factor in 16 children who developed HUS after Escherichia coli O157:H7 infection and in 29 infected children who did not develop this complication. Von Willebrand factor-cleaving metalloprotease activity was normal in all subjects, but von Willebrand factor size was decreased in the plasma of each of 16 patients with HUS. The decrease in circulating von Willebrand factor size correlated with the severity of thrombocytopenia and was proportional to an increase in von Willebrand factor proteolytic fragments in plasma. Immunohistochemical studies of the kidneys in four additional patients who died of HUS demonstrated glomerular thrombi in three patients, and arterial and arteriolar thrombi in one patient. The glomerular thrombi contained fibrin but little or no von Willebrand factor. A decrease in large von Willebrand factor multimers, presumably caused by enhanced proteolysis from abnormal shear stress in the microcirculation, is common in HUS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328948     DOI: 10.1203/00006450-200105000-00008

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  38 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 2.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

3.  Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Authors:  K G J Pollock; D Young; T J Beattie; W T A Todd
Journal:  Epidemiol Infect       Date:  2007-03-05       Impact factor: 2.451

Review 4.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

5.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

6.  Cardiac ischemia during hemolytic uremic syndrome.

Authors:  Meena Thayu; Wayne L Chandler; Srdjan Jelacic; Carrie A Gordon; Geoffrey L Rosenthal; Phillip I Tarr
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

7.  Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor.

Authors:  Nathan C Lo; Nancy A Turner; Miguel A Cruz; Joel Moake
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 8.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 9.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

10.  Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.

Authors:  Trung C Nguyen; Yong Y Han; Joseph E Kiss; Mark W Hall; Andrea Cortese Hassett; Ron Jaffe; Richard A Orr; Janine Janosky; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.